Multifactorial evaluation and treatment of persons with a high risk of recurrent falling was not cost-effective by Peeters, G. M. E. E. et al.
ORIGINAL ARTICLE
Multifactorial evaluation and treatment of persons
with a high risk of recurrent falling was not cost-effective
G. M. E. E. Peeters & M. W. Heymans & O. J. de Vries &
L. M. Bouter & P. Lips & M. W. van Tulder
Received: 26 April 2010 /Accepted: 15 September 2010 /Published online: 20 October 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Summary This study evaluated the cost-effectiveness of
multifactorial evaluation and treatment of fall risk factors in
community-dwelling older persons at high risk of falling.
The intervention and usual care groups did not differ in fall
risk or costs. The multifactorial approach was not cost-
effective compared to usual care in this group.
Introduction International guidelines recommend multifac-
torial evaluation and tailored treatment of risk factors to
reduce falling in older persons. The cost-effectiveness may
be enhanced in high-risk persons. Our study evaluates the
cost-effectiveness of multifactorial evaluation and treatment
of fall risk factors in community-dwelling older persons at
high risk of recurrent falling.
Methods An economic evaluation was conducted along-
side a randomised controlled trial. Participants
(≥65 years) with a high risk of recurrent falling were
randomised into an intervention (n=106) and usual care
group (n=111). The intervention consisted of multifacto-
rial assessment and treatment of fall risk factors. Clinical
outcomes were proportions of fallers and utility during
1 year. Costs were measured using questionnaires at 3, 6
and 12 months after baseline and valued using cost prices,
if available, and guideline prices. Differences in costs and
cost-effectiveness were analysed using bootstrapping.
Cost-effectiveness planes and acceptability curves were
presented.
Results During 1 year, 52% and 56% of intervention and
usual care participants reported at least one fall,
respectively. The clinical outcome measures did not
differ between the two groups. The mean costs were
Euro 7,740 (SD 9,129) in the intervention group and
Euro 6,838 (SD 8,623) in the usual care group (mean
difference Euro 902, bootstrapped 95% CI: −1,534 to
3,357). Cost-effectiveness planes and acceptability curves
indicated that multifactorial evaluation and treatment of
fall risk factors was not cost-effective compared with
usual care.
Conclusions Multifactorial evaluation and treatment of
persons with a high risk of recurrent falling was not cost-
effective compared to usual care.
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Fall incidents are the third cause of chronic disability in
older persons according to the WHO [1]. One in three
community-dwelling persons of 65 years and older falls
once per year [2–4] and about 25% of the fallers consult the
general practitioner or Accidents and Emergency (A&E)
department of a hospital [5, 6]. The consequences may be
severe and approximately 5% of the falls result in a fracture
[6]. In older persons consulting the A&E department after a
fall, the average total costs from the moment of the fall to
1 year later have been estimated at Euro 4,991 [7]. Because
of the increasing number of older persons in the next
decades, the number of fallers is expected to rise.
Preventive measures are needed to reduce the number of
falls and related costs. Although many trials have evaluated
the effectiveness of preventive interventions, few have
evaluated the cost-effectiveness of these interventions.
Over the past decade, many randomised controlled trials
(RCTs) have studied the effectiveness of multifactorial
interventions, i.e. multifactorial evaluation and treatment of
fall risk factors [8–16]. Despite conflicting results among
original trials, meta-analyses seem to favour multifactorial
interventions [17–19]. Although the evidence does not
seem to be conclusive, international guidelines recommend
multifactorial evaluation and tailored treatment of fall risk
factors [20, 21]. Increasing numbers of geriatricians initiate
fall prevention programs based on these guidelines. Given
the large number of fallers, evaluation and treatment of
every older person after a fall is not feasible. It may be
more cost-effective to limit the intervention to older persons
with the highest fall risk [22].
To our knowledge, only two studies have focused on the
cost-effectiveness of multifactorial interventions among
community-dwelling older persons. The first study was
conducted in the US and found that the intervention was
more cost-effective than usual care and this effect was the
largest in the high risk group [23]. The second study found
that the evaluation of fall risk factors by a geriatrician and
occupational therapist was not cost-effective as compared
with usual care in The Netherlands [7]. However, the first
study did not include patient costs (e.g. informal care and
self acquired aids and adaptations), and in the second study,
the compliance rate was low and the patients were not
screened for fall risk [24].
Our study aims to evaluate the cost-effectiveness of
multifactorial evaluation and treatment of fall risk factors
compared to usual care in community-dwelling older
persons at high risk of recurrent falling. The economic
evaluation is conducted from a societal perspective. The
effectiveness of this intervention has been described in
detail elsewhere [25]. Although the intervention did not
reduce the fall risk as compared with usual care, we believe
it is important to evaluate the costs in both groups because
of three reasons. First, the intervention may have reduced
the severity of the consequences of new falls and, on the
long term, may be cost-saving compared to usual care.
Second, if the intervention is associated with higher costs
than usual care, this would be an argument not to
implement the intervention. This is particularly important
because fall prevention programs are becoming increasing-
ly more popular in The Netherlands and other countries.
Third, to avoid publication bias, it is important to publish
results from all economic evaluations regardless of their
results. If only “positive” results would be published, policy
makers would use misleading information and policy
decisions would be invalid.
Methods
The study was designed as an economic evaluation
alongside a RCT. The design of this study was described
in detail elsewhere [26]. This paragraph summarizes the
details that are relevant for this paper.
Study population
The study population consisted of persons of 65 years and
older who consulted their general practitioner or the A&E
department of the VU University Medical Center, Amster-
dam, The Netherlands, after a fall accident between April
2005 and July 2007. Inclusion criteria were living inde-
pendently or in a residential home, living in the vicinity of
the VU University Medical Center and having experienced
a fall less than 3 months ago. Exclusion criteria were
inability to sign informed consent, inability to provide a
detailed history and scoring less than 24 points on the Mini-
Mental State Examination, fall due to a traffic or occupa-
tional accident, living in a nursing home and acute
pathology requiring long-term rehabilitation such as a
stroke. During the first home visit within 3 months after
the presenting fall, the risk of recurrent falling was assessed
using the validated LASA fall risk profile [27, 28]. This
risk profile consists of the following nine items: two or
more falls in the preceding year, regular dizziness,
functional limitations, poor grip strength, low body weight,
having a cat or dog in the household, fear of falling, high
alcohol intake and a high level of education. After the first
home visit, 36 participants did not meet the inclusion
criteria and were excluded. Participants who scored 7 points
or lower on the fall risk profile were considered at low risk
of recurrent falling and were excluded from the RCT and
economic evaluation. Participants with a risk score of 8 or
higher and participants living in a residential home were
considered to be at high risk of recurrent falling. These
2188 Osteoporos Int (2011) 22:2187–2196high-risk participants were randomly allocated to the
intervention and usual care groups. At the end of the home
visit, an appointment was made to visit the geriatric
outpatient clinic for persons in the intervention group. No
extra assessments or visits were done in the usual care
group.
Intervention
The multifactorial transmural intervention started with a
visit to the geriatric outpatient clinic. A multifactorial fall
risk assessment was conducted by the geriatrician to
identify modifiable fall risk factors. The assessment of fall
risk factors and the design of the treatment plan were based
on the Dutch Institute for Healthcare Improvement (CBO)
guideline “Prevention of fall incidents in older persons”
[20]. The assessment consisted of a general medical history,
a fall and mobility history, and physical examination with
special emphasis on signs of postural hypotension, neuro-
logical deficits, visual disturbances, gait and mobility
disorders and medication. Additional diagnostic tests were
performed if indicated (e.g. laboratory tests or imaging).
Based on the assessment of fall risk factors, an individually
tailored treatment regimen aimed at reduction of the fall
risk was composed in collaboration with the general
practitioner of the participant. The multifactorial treatment
consisted of, for example, withdrawal of psychotropic
drugs, balance and strength exercises by a physical
therapist, home hazard reduction by an occupational
therapist or referral to an ophthalmologist or cardiologist.
Usual care
During the study period, usual care in The Netherlands after
a fall mainly consisted of treatment of the consequences of
the fall. Although a national guideline was released in 2004
[20], multifactorial fall risk prevention had not yet been
implemented by general practitioners or at the A&E
departments.
Clinical outcome measures
Clinical outcome measures of the economic evaluation
were the prevalence of fallers and recurrent fallers and
utility (quality of life). All participants reported falls during
at least 1 year using a fall calendar [4]. The participants
ticked per week whether they did or did not fall. Once per
3 months the participants returned a calendar sheet by mail.
When no sheet was received, or when the sheet was
completed incorrectly, we inquired by telephone whether
and when the participant had fallen in the past 3 months. A
fall was defined as an unintentional change in position
resulting in coming to rest at a lower level or on the ground
[29]. Recurrent falling was defined as having fallen twice or
more within a 6-month period [27].
Utility was assessed at baseline and after 1 year using
the EuroQol (EQ-5D) [30]. This questionnaire was
developed to generate a general index of experienced
health. Health states were estimated using reference values
from a representative Dutch sample (range 0, death, to 1,
optimal health) [31]. Quality Adjusted Life Years
(QALYs) were calculated as the area under the curve,
with straight-line interpolation between utility at baseline
and 1-year follow-up.
Costs
The economic evaluation was conducted from a societal
perspective. Healthcare costs (e.g. geriatrician consult,
general practitioner care, specialist care, therapy, medica-
tion, hospitalisation and nursing home admittance), patient
and family costs (e.g. informal care), and costs in other
sectors (e.g. medical devices, home modifications and
transportation aids) were measured during 1 year after
baseline (the footnote of Table 4 provides an overview of
all cost categories and all items included per category). All
health-related costs were taken into account, since it is
impossible to distinguish fall-related from non-fall-related
costs. Medical interventions undertaken to treat other health
problems can directly or indirectly affect the fall risk. For
example, someone may visit his GP for a monthly blood
pressure measurement and subsequent adjustments in his
medication may affect his fall risk. Productivity costs were
not included, because all persons were above 65, the age of
retirement in The Netherlands.
The participants received a cost-evaluation questionnaire
3, 6 and 12 months after the first home visit. The 3- and 6-
months questionnaires were sent by mail, the 12-months
questionnaire was assessed by a research assistant during a
second home visit 1 year after baseline. Healthcare costs
were valued using the Dutch guideline prices published in
the “Handbook for cost studies, methods and guidelines for
economic evaluation in health care” [32]. This handbook
contains prices for, for example, hospital admittance,
physiotherapy and general practitioner consultation. The
costs of medication use were estimated based on the
medicine use reported during the first home visit at baseline
and the second home visit after 12 months. Participants
were asked which medications (both over the counter and
prescribed drugs) they had used during the previous
2 weeks. Generic names and doses were copied directly
from the containers. Also, the frequency and dose per
intake were reported. Since the number of units taken
during the year of follow-up was not known, an estimation
was made based on the available information and the
following assumptions: (1) medicine for chronic use
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medicine for chronic use reported at one home visit=
frequency × 0.5 × 365 days; (3) medicine for temporary
use=frequency × 0.5 × recommended duration; (4)
medicine for incidental use=10% from the number of
units in case of chronic use and (5) for participants who
dropped out before the second home visit, the number of
units was estimated based on half the number of days until
drop out. In the second, third and fifth assumption, it was
unknown how long the participant had been taking a
medication on the time point of assessment. Therefore,
0.5 × the expected total duration was believed to be the
overall best estimated duration. Information on recom-
mended duration of medications was obtained from the
pharmaceutical guidelines published by the Dutch Health
Insurance Board (CVZ) [33]. The prices per medication
were obtained from the Royal Dutch Society of Pharmacy
[34]. Costs of healthcare devices, aids and adaptations
were estimated by asking retail prices from three suppliers
in The Netherlands. For each product, the average price
was used. All costs were expressed in 2007 Euros.
Statistical methods
Baseline characteristics were estimated for the intervention
and usual care groups. The economic evaluation was
performed according to the intention-to-treat principle.
The incremental cost-effectiveness ratios were calculated
(differences in costs divided by differences in effects
between the intervention and usual care groups). Imputation
of missing values was done using the Multivariate
Imputation by Chained Equations algorithm [35]. The
imputation model, which was used to estimate the imputed
values, included the variables group randomisation, age,
sex, education level, Mini-Mental State Examination,
number of chronic diseases and score on the fall risk
profile. According to the variables in the imputation model,
imputed values were based on linear, logistic or polytomous
regression estimates. Imputation of cost variables was done
before multiplying volumes by cost prices. For medication,
the total costs were imputed. Five imputed datasets were
created. The quality of the imputations depends on the
amount of missing data. When this does not exceed 50%, as
in our study (approximately 10%), five imputations are
enough to get valid cost estimates [36]. The analyses were
done in each dataset and presented are the pooled results of
the five imputed datasets as described below.
Arithmetic mean (standard deviation, SD) costs were
computed for both groups. Means and differences in costs
and effects were estimated in each imputed dataset and
results were combined by using Rubin’s rules [37]. Mean
difference between groups and the associated bias-
corrected and accelerated confidence intervals were calcu-
lated using bootstrapping techniques. Bootstrap analyses to
construct bias-corrected and accelerated confidence inter-
vals were done in each imputed dataset and results were
pooled [38].
The economic evaluation involved estimating incremental
cost-effectiveness ratios (ICER) of the incremental costs per
avoided faller and recurrent faller. Also, an incremental cost–
utility ratio (ICUR) was estimated for the incremental costs
per QALY. ICERs and ICUR were estimated by dividing the
difference in costs by the difference in effects (ICER) or
utility (ICUR; intervention minus usual care) in the imputed
datasets. Uncertainty around the ratios was estimated using
bootstrapping techniques and graphically represented on a
cost-effectiveness plane. Cost-effectiveness acceptability
curves were presented to indicate the probability that the
multifactorial transmural intervention was cost-effective
given a ceiling ratio (i.e. maximum costs) that policymakers
are willing to invest. To evaluate the influence of the missing
values and their substitution by using multiple imputation
techniques, we performed a sensitivity analysis. In this way,
we were able to study the influence of missingness on the
precision of the study results and check whether missing
values were missing completely at random.
Results
Of the 2,015 persons who visited the A&E or general
practitioner after a fall, 581 were not eligible, 771 refused
participation, 63 were deceased before contact and 600
were willing to participate (Fig. 1). Of the 600 persons who
signed informed consent, 32 were excluded, four did not
want to participate, and 347 were assigned to the low risk
group leaving 217 to be randomised into the intervention
(n=106) and usual care groups (n=111). The persons who
refused to participate were more often contacted via the
A&E department (p<0.001), but did not differ from
participants in age or sex (p≥0.08). Of all 217 participants
included in the analyses, eight died (3.7%; seven in the
usual care group, one in the intervention group) and 22
dropped out (10.1%; ten in the usual care group, 12 in the
intervention group) during follow-up. Persons who dropped
out in the intervention group did not differ from persons in
the control group regarding age, sex, level of education, ≥2
falls in the preceding year and score on the fall risk profile
(p>0.42).
The groups were similar at baseline with regard to
potential confounding factors (Table 1). The average age
was 79.0 years (SD 7.7) in the intervention group and
80.6 years (SD 7.0) in the usual care group. The
percentages of women were 67 in the intervention group
and 74 in the usual care group. The median utility at
baseline was 0.78 [Interquartile range 0.65–0.84] in both
2190 Osteoporos Int (2011) 22:2187–2196groups. Table 2 gives an overview of the recommendations
given in the intervention group and the adherence to these
recommendations. The numbers of fallers during 1 year of
follow-up were 55 (52%) and 62 (56%), and the numbers of
recurrent fallers were 37 (35%) and 35 (32%) in the
intervention and usual care groups, respectively (Table 3).
During follow-up, five persons in the intervention group
and five persons in the usual care group suffered a fracture,
of whom two persons in the intervention group and no
persons in the usual care group had multiple fractures. In
addition, the difference in QALYs gained over 1 year of
follow-up between the intervention, and usual group was
small and not statistically significant.
The total mean costs were Euro 7,740 (SD 9,129) in the
intervention group and Euro 6,838 (SD 8,623) in the usual
care group (Table 4). The intervention and usual care
groups did not differ in total costs (Euro 902; 95% CI:
−1,534 to 3,357). Also, the mean healthcare costs and the
mean patient and family costs did not differ significantly
between the groups (Table 4). Figure 2 shows the cost-
effectiveness planes for the intervention group in comparison
with the usual care group for the outcomes fallers, recurrent
fallers and QALYs gained. In all three planes, the cost-effect
pairs cluster around the origin, indicating neither large nor
significant differences in costs and effects. The percentage of
fallers was 4.0% lower in the intervention group as compared
with the usual care group and the costs were Euro 902 higher,
resulting in an ICER of 226. In other words, the costs per
percentage decrease in fallers are 226 Euros. Since the
percentage of recurrent fallers was higher in the intervention
than in the usual care group, the ICER for recurrent falling
was negative (ICER=−280). The acceptability curves show
that the maximum probability of cost-effectiveness with
respect to the proportion of fallers was obtained at a ceiling
ratio of Euro 10,000 (Fig. 2). This indicates that if Euro
10,000 were invested, the probability that the intervention
would reduce the percentage of fallers by 1% was 0.80.
Likewise, if Euro 300,000 were invested, the probability that
the intervention would improve the quality of life (utility) by
one point was only about 0.30. Since the costs were higher
and effects were smaller for the outcome recurrent fallers, the
intervention was not cost-effective at any given ceiling ratio
and therefore this curve was not included in Fig. 2.
To test the impact of imputation, the analyses were
repeated with the 73 and 74 participants in the intervention
and usual care groups, respectively, who had complete data.
The total costs in the intervention group were Euro 220
lower than in the usual care group; however, this difference
was not statistically significant (bootstrapped 95% CI:
−2,754 to 2,224). Since the percentage of fallers and
recurrent fallers did not differ between the groups, the
cost-effectiveness ratios clustered around the origin. ICERs
were 116 for fallers, −120 for recurrent fallers and 23,044
for QALYs (data not shown).
Discussion
This study investigated the cost-effectiveness of multifac-
torial evaluation and treatment of fall risk factors in persons
2015 persons consulted the 
A&E department or primary 
care physician after a fall 
High risk group 
(n=217) 
771 persons refused to participate: 
- no time or did not want to (n=555) 
- did not expect benefit (n=148) 
- objected against research (n=6) 
- other or no reason given (n=62) 
581 persons  were excluded: 
- presenting fall >3 months ago (n=326) 
- unable to provide fall history (n=102) 
- did not fall (n=75) 
- living in nursing home (n=48) 
- fall caused by trafic accident (n=14) 
- did not live in vicinity of medical 
center (n=11) 
- fell    2 between presenting fall and 
home visit (n=3) 
- <65 years (n=2) 
63 persons deceased before contact 
32 persons were excluded during home 
visit:
- MMSE<24 (n=23) 
- unable to provide fall history (n=3) 
- presenting fall >3 months ago (n=3) 
- fell    2 between presenting fall and
home visit (n=2)  
excluded from 
RCT 
Usual care 
group 
(n=111) 
Intervention 
group 
(n=106) 
600 persons signed informed 
consent and completed the fall 
risk profile 
Low risk group 
(n=347) 
Fig. 1 Flow chart of participants included in the study
Intervention group (n=106) Usual care group (n=111)
Age (mean (SD)) 79.0 (7.7) 80.6 (7.0)
Sex (% women) 67.0 73.9
Education (% ≥11 years of education) 61.9 55.0
Living situation (% home)
a 3.8 4.5
Baseline utility (EQ-5D) 0.78 [0.65–0.84] 0.78 [0.65–0.84]
Falls preceding year (% ≥2 falls) 78.6 75.0
Table 1 Baseline characteristics
aLiving in a home for the elderly
versus community-dwelling
Osteoporos Int (2011) 22:2187–2196 2191with a high risk of recurrent falling. The intervention did
not reduce the fall risk as compared with usual care during
1 year of follow-up. The average costs made from a societal
perspective in persons with a high risk of recurrent falling
who received the multifactorial intervention was Euro
7,740 in 1 year, which was Euro 902 higher than in the
control group that received usual care.
Explanations for a lack of differences in fall risk between
the two groups have been described in detail elsewhere. In
short, one explanation may be a lack of contrast and
second, the intervention may not be adequate in the high
risk group that we selected [25]. Lack of contrast may be
due to limited adherence in the intervention group and/or
improved usual care and increased awareness of the fall risk
in the usual care group. Although the adherence rates are
within the ranges reported in previous fall prevention trials,
only about half of the recommendations have been fully
adhered to. Higher adherence rates might have led to fewer
falls, but also to higher costs. Therefore, it is impossible to
judge whether better adherence would have improved the
cost-effectiveness of this intervention.
The mean costs of participants who received the
intervention were somewhat, but not statistically signifi-
cant, higher than in participants who received usual care.
Closer inspection of the costs per category reveals that
medication costs were higher in the intervention group and
these participants also tended to have higher costs of allied
health care. Revision of medication was a facet of the
Table 2 Specification of recommendations and adherence in the intervention group
Type of recommendation Adhered to recommendation
Total number Yes Alternative
a No Unknown
Referrals 176 101 25 25 25
Physical therapy 80 47 11 11 11
Occupational therapy 30 17 5 5 3
Ophthalmologist 20 10 1 3 6
Cardiologist 11 8 1 0 2
Other referrals 35 19 7 6 3
Medication 111 49 19 22 21
Initiation Calcium/vitamin D 19 11 3 4 1
Discontinue benzodiazepines 17 6 5 4 2
Other medication changes 75 32 11 14 18
Instructions 52 27 13 9 3
Risky behaviour 8 4 1 3 0
Reduce alcohol intake 10 4 3 2 1
Other instructions 34 19 9 4 2
Mixed recommendations 19 10 2 4 4
Use of compression stockings 15 8 1 3 3
Other recommendations 4 2 1 1 1
Total recommendations 358 187 59 60 52
% of recommendations 52.2 16.5 16.8 14.5
aAlternative indicates that the participant took action in response to the recommendation, but did not exactly or only partially did what was
recommended (this Table has been previously published in [25])
Table 3 Clinical outcomes at 12 months and incremental cost-effectiveness ratios
Intervention group Usual care group Difference 95% CI ICER
% fallers 52 56 −4.0 −17 to 9 226
% recurrent fallers 31 28 3.2 −9t o1 5 −280
Mean (SD) QALY 0.76 (0.11) 0.76 (0.14) −0.004 −0.021 to 0.029 −232,533
a
Presented are the pooled mean differences and 95% confidence intervals in the clinical outcome measures and incremental cost-effectiveness
ratios (ICER)
aIncremental cost–utility ratio
2192 Osteoporos Int (2011) 22:2187–2196intervention: 24% of the participants in the intervention
group were recommended to reduce or stop some medi-
cations while 33% of the participants were recommended to
start using certain medications. The costs per unit of the
stopped medications (mostly psychopharmaca) were lower
than the costs per unit of the started medications (mostly
osteoporosis medication). This, in combination with the net
rise in number of medications, may explain the higher costs
in the intervention group. The higher costs of allied health
care were anticipated because 81% of the participants in the
intervention group were referred to the physiotherapist and/
or occupational therapist. However, we also anticipated
higher costs for healthcare devices, aids and adaptations.
Lack of differences in costs between the two groups may be
because the intervention group did not adhere to the
recommendations given by the occupational therapist
regarding aids and adaptations and/or the usual care group
also acquired aids and adaptations. The latter explanation is
likely, since in The Netherlands, devices such as walking
aids, shower seats and platform scooters are easily
accessible via health insurances and municipalities. Also,
some participants from the usual care group declared that
completing the questionnaires notified them that aids and
adaptations may be helpful for them.
Two previous studies have evaluated the cost-
effectiveness of multifactorial fall prevention programs.
Both our study and a recently published study which was
conducted in Maastricht, The Netherlands did not show a
difference in either costs or effects between the intervention
and usual care groups [7]. The total costs in our study were
somewhat higher than in the Maastricht study. However, in
the Maastricht study all patients who consulted the A&E
department after a fall were considered at high risk of
falling, while we screened these patients to select those with
a high risk of recurrent falling. Consequently, our sample
was older and had a higher fall risk. In addition, the
intervention participants in our study received more
recommendations per person and the compliance rate was
higher [24]. Finally, they expressed costs in 2004 Euros,
whereas we expressed costs in 2007 Euros (1.0452% price
Table 4 Mean health care, patient and family, and total costs in Euros in the intervention and usual care groups
Intervention (n=106) Usual care (n=111) Bootstrap 95% CI
Healthcare costs 5995 (8399) 4858 (7606) −1091 to 3371
- General practitioner
a 167 (242) 136 (144) −12 to 101
- Hospital-related
b 2195 (4755) 1720 (3950) −672 to 1741
- Paramedic and alternative medicine
c 894 (1067) 644 (861) −8 to 526
- Formal care
d 1369 (4338) 1614 (5827) −1945 to 980
- Medication
e 1370 (4870) 745 (685) 64 to 2655
Patient and family costs 404 (695) 409 (1079) −339 to 207
- Informal care
f 313 (682) 310 (1080) −298 to 217
- Other costs
g 90 (111) 99 (91) −37 to 23
Costs in other sectors 1332 (2203) 1566 (3285) −1133 to 445
- Transportation
h 413 (1202) 739 (2623) −1137 to 241
- Healthcare devices, aids and adaptations
i 843 (1543) 759 (1613) −355 to 538
Total costs 7740 (9129) 6838 (8623) −1534 to 3357
Presented are pooled means (SD) and the bias-corrected and accelerated bootstrapped 95% confidence intervals in Euros
aGeneral practitioner consultations (including telephone consultations and home visits)
bSpecialized physician consultations (e.g. ophthalmologist, internal physician, geriatrician) emergency department consultations, hospital
admittance and surgeries
cConsultations of physiotherapist, occupational therapist and other therapists including alternative medicine
dHome care (i.e. housekeeping, personal care, meal preparation, preparation and administration of medications and wound care), day care and
admittance to nursing home or home for the elderly
eOver the counter and prescribed drugs
fCare received from family, neighbours and friends
gPedicure and exercise programs (other than physiotherapy)
hWheel chair, platform scooter, handicapped parking placard and bicycle
iRollator, crutches, walking stick, Zimmer frame, orthopaedic shoes, brace/splint, compression stocking, hip protector, incontinence products,
personal alarm, glasses, hearing aids, handrails, removing thresholds, smoothing surfaces, ramp, stair lift, replacing bathtub by shower, shower
seat, (anti-slip) floor covering, electric door opener, high toilet, toilet arm rests, toilet chair, bath seat/lift, bath mat, raised chair, rise chair, working
chair, bed raisers, height adjustable bed and bed triangle
Osteoporos Int (2011) 22:2187–2196 2193index from 2004 to 2007). In 1996, a similar study was
conducted in New Haven, CT [23]. In this US study, the
multifactorial targeted prevention program reduced the fall
rate by almost 50% and the costs by 26% in participants with
a high fall risk. However, two differences should be
emphasized: first, the US study did not include patient and
family costs, and second, usual care more often includes home
modifications in The Netherlands than in the US. In The
Netherlands, municipalities are responsible for their inhab-
itants to live as safely and independently as possible in their
own environment and financial resources are available to
improve the home environment for people who are disabled.
In the literature, it has been hypothesized that the cost-
effectiveness of multifactorial evaluation and treatment of
Fig. 2 Cost-effectiveness planes and acceptability curves for the
multifactorial evaluation and treatment of fall risk factors in
comparison with usual care. Top left: cost-effectiveness plane differ-
ences in percentage of fallers. Top right: cost-effectiveness plane for
differences in percentage of recurrent fallers. Bottom left: cost-
effectiveness plane for differences in utility (QALY) after 1 year.
Bottom right: acceptability curves presenting the probability of the
intervention being cost-effective as compared with usual care at
various ceiling ratios of costs, presented for fallers (solid line) and
QALYs (dashed line). For a detailed explanation of the Cost-
Effectiveness Acceptability Curves (CEAC), we would like to refer
readers to [40]). The panels in the cost-effectiveness planes display the
percentages of estimated ratios per quadrant of the plane. North East
quadrant intervention is more effective and more expensive, South
East quadrant intervention is more effective and less expensive, South
West quadrant intervention is less effective and less expensive, North
West quadrant intervention is less effective and more expensive
2194 Osteoporos Int (2011) 22:2187–2196fall risk factors may be improved by selecting persons with
a high risk of falling [22]. The current results do not
support this hypothesis. Over the past few years, many
geriatricians have initiated fall clinics with multifactorial
preventive programs in The Netherlands. However, both the
current study and the Maastricht study showed that this
approach reduces neither the fall rate nor the costs among
high-risk patients and is thus not superior to usual care in
The Netherlands. It is recommended that multifactorial
evaluation and treatment of fall risk factors in older persons
with a high fall risk should not be implemented in The
Netherlands. Since healthcare costs and the content of usual
care differ across countries, generalizing the current results
to other countries may not be relevant.
This study included both community-dwelling persons
and residential home residents. In The Netherlands, persons
living in a residential home, usually require either some
assistance for (instrumental) activities of daily living or
services to prevent social isolation, but still have a high
level of autonomy. The assistance needed is limited to fixed
times of the day, e.g. help to get out of bed or to take
medication. Additional frequent (non-)structural help, e.g.
assistance to go the toilet or get a drink, or low level of
autonomy classifies for nursing home admittance. The
proportion of persons living in a residential home in this
study was too low to analyse whether the cost-effectiveness
of the current intervention differs between community-
dwelling and residential home participants.
Some limitations of this study need to be pointed out.
First, the main aim of this study was to study the
effectiveness of the intervention that is why the power
calculation was based on a falls reduction rather than
QALYs or costs. Power calculations based on QALYs or
costs would have been difficult given the absence of
information in the literature on potential effects of the
intervention on these outcomes. Second, only 150 persons
completed all three cost-evaluation questionnaires. Partic-
ipants who did not return all questionnaires were older and
frailer, and it is likely that the costs among these persons
are higher. However, the proportions of missing question-
naires did not differ between the intervention and usual care
groups. The total mean costs per group may be under-
estimated, but not the difference in costs. Third, the
medication costs were estimated based on the assumptions
described in the method. These assumptions introduce
uncertainty in the estimation of the total costs and
consequently the incremental cost-effectiveness ratios.
However, the same assumptions were used in both groups.
Furthermore, repeating the analyses without the medication
costs resulted in a smaller difference in the total costs
between the two groups, and thus a smaller ICER. Fourth,
imputation of missing values introduces extra uncertainty in
the estimation of the effects. However, sensitivity analyses
among persons with complete data revealed that the impact
of imputation did not alter the results. Fifth, we did not
measure the costs in the low risk group. Thus, no
conclusions can be drawn with respect to the costs or
cost-effectiveness of the screening for risk of recurrent
falling. In addition, we also did not measure costs at
baseline because at that time the intervention had not
started yet. We measured costs after randomization. In any
economic evaluation, differences at baseline might explain
differences indentified during follow-up. However, our
randomization was successful, and no relevant baseline
differences were observed. Consequently, it is very unlikely
that there would have been any baseline differences in
costs. Finally, recent literature suggests that statistical
analysis in falls studies that allow for analysing all falls
rather than a fall are more sensitive and might have picked
up a difference between the intervention and usual care
group that we did not find with the outcome measures
“faller” and “recurrent faller” [39]. However, because of
ethicalconsiderations,whenapersonfrom theusualcaregroup
fell twice or more within 6 months during follow-up (recurrent
faller), we informed his/her GP of the person’s increased fall
risk and advised the GP to initiate preventive measures. This
may have affected the fall risk and number of falls during the
remainder of the follow-up. Therefore, we did not present the
number of falls as a primary outcome in this study.
In conclusion, multifactorial evaluation and treatment of
persons with a high risk of recurrent falling does not seem
cost-effective compared to usual care.
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